H. Lundbeck A/S (Lundbeck) will present data from its movement disorders pipeline at the International Congress of Parkinson’s Disease and Movement Disorders (MDS 2026), being held in Seoul, South Korea, from October 4 to 8, 2026. The presentations cover Multiple System Atrophy (MSA) and advanced Parkinson’s Disease (PD), focusing on disease progression, clinical trial measures, biomarkers and investigational therapies.

A key presentation will provide baseline characteristics of participants enrolled in MASCOT, Lundbeck’s ongoing Phase 3 trial evaluating amlenetug in MSA. The study enrolled 401 participants with clinically probable or clinically established MSA, including both MSA-C and MSA-P. It is evaluating the safety and efficacy of amlenetug versus placebo over a 72-week double-blind treatment period, with results expected in the third quarter of 2027.

MSA is a rare and rapidly progressing neurodegenerative disease associated with damage to nerve cells involved in movement, balance and autonomic functions. There is currently no approved treatment that slows the clinical progression of MSA.

Lundbeck will also present research addressing clinical development challenges in MSA. The data include analyses supporting the use of the modified Unified Multiple System Atrophy Rating Scale Part I (mUMSARS Part I) as a clinical trial endpoint, validation of the Chinese version of UMSARS, and studies of cerebrospinal fluid biomarkers for disease detection, differential diagnosis and monitoring.

Additional MSA research includes a US observational database study comparing healthcare costs and resource utilisation among people with MSA and Parkinson’s disease. The study found higher healthcare costs and healthcare resource utilisation among people with MSA, highlighting the healthcare burden associated with the rapidly progressing condition.

In Parkinson’s disease, Lundbeck will present new Phase 1b data for Lu AF28996, an investigational oral D1-like/D2-like dopamine receptor agonist being developed for people with advanced PD and motor complications. The 18-week open-label Phase 1b study evaluated the safety, tolerability and clinical effects of Lu AF28996 in people with inadequately controlled advanced PD experiencing motor fluctuations, with or without dyskinesia.

The clinical findings will be supported by preclinical research examining the relationship between dose, motor efficacy and dyskinesia in a primate model of Parkinson’s disease.

Parkinson’s disease is a progressive neurological disorder characterised by motor symptoms such as slowness of movement, tremor and rigidity, as well as non-motor symptoms. Long-term treatment with levodopa can be associated with motor complications, including OFF-time and dyskinesia, which can affect daily functioning and quality of life.

Lu AF28996 and amlenetug are investigational compounds and have not been approved by any regulatory authority. Their safety and efficacy have not been established.